The Feasibility and Efficacy of a Two-week MCT Treatment of Anxiety Disorders in a Group Setting
NCT ID: NCT05402306
Last Updated: 2022-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2022-02-28
2023-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Research suggests that Metacognitive Therapy (MCT) is an effective treatment for anxiety disorders. However, MCT has not previously been used on inpatients over a two-week period. To make the treatment tangible for patients and easy to administer for therapists over a short time, attention training technique (ATT) will mainly be used as a changing technique.
The main aim of the study is to explore the feasibility and efficacy of intensive and short-term MCT for anxiety disorders in a group setting.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brief Group Psychotherapy for Anxiety and Depression
NCT04489641
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
NCT02306356
Neurobiological Markers of Treatment Response for Anxiety and OCD
NCT05663489
Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders
NCT03033056
Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder
NCT06834217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria: Adults ranging from 18 to 30 years of age meeting diagnostic criteria for generalised anxiety disorder, social phobia, and/or panic disorder with or without agoraphobia will be included in the study. Further the participants must be able to communicate in Norwegian and provide written consent.
Exclusion criteria: Exclusion criteria will be ongoing drug abuse, history of psychotic episodes, current suicidality, or participants not able to adapt to an intensive group format.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
A two-week intensive group treatment with MCT mainly focusing on attention training. The participants will be allocated into treatment in groups of six. Group sessions will be conducted two times a day for approximately 60 minutes.
Treatment group
Group metacognitive therapy, mainly with attention training technique over two weeks.
Waitlist control group
Cohorts of 12 included patients will be randomly assigned to active treatment or waitlist for two weeks. The waitlist patients will receive the same treatment immediately after four-week waiting period.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment group
Group metacognitive therapy, mainly with attention training technique over two weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meeting diagnostic criteria for generalised anxiety disorder, social phobia, and/or panic disorder with or without agoraphobia
* Provide written consent to partake in the study
Exclusion Criteria
* History of psychotic episodes
* Current suicidality
* Participants not able to adapt to an intensive group format
18 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Modum Bad
OTHER
University of Oslo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sverre Urnes Johnson
Associate Professor Sverre Urnes Johnson
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sverre Urnes Johnson, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Oslo & Modum Bad
Henrik Nordahl, PhD
Role: PRINCIPAL_INVESTIGATOR
Norwegian University of Science and Technology
KariAnne Vrabel, PhD
Role: PRINCIPAL_INVESTIGATOR
Modum bad & University of Oslo
Asle Hoffart, PhD
Role: PRINCIPAL_INVESTIGATOR
Modum Bad & University of Oslo
Therese R. Snuggerud, Masters
Role: PRINCIPAL_INVESTIGATOR
Modum Bad
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Modum Bad
Vikersund, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sverre Urnes Johnson, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REK269896
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.